WO2007102736A3 - Interfering in activation of an immune cell by influencing interaction of lair and collagen. - Google Patents

Interfering in activation of an immune cell by influencing interaction of lair and collagen. Download PDF

Info

Publication number
WO2007102736A3
WO2007102736A3 PCT/NL2007/050093 NL2007050093W WO2007102736A3 WO 2007102736 A3 WO2007102736 A3 WO 2007102736A3 NL 2007050093 W NL2007050093 W NL 2007050093W WO 2007102736 A3 WO2007102736 A3 WO 2007102736A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
immune cell
lair
collagen
interfering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2007/050093
Other languages
French (fr)
Other versions
WO2007102736A2 (en
Inventor
Linde Meyaard
Robert Jan Lebbink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitair Medisch Centrum Utrecht
Universiteit Utrecht
Original Assignee
Rijksuniversiteit Utrecht
Universitair Medisch Centrum Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rijksuniversiteit Utrecht, Universitair Medisch Centrum Utrecht filed Critical Rijksuniversiteit Utrecht
Priority to EP07715911A priority Critical patent/EP2004850A2/en
Priority to US12/281,741 priority patent/US20090304686A1/en
Publication of WO2007102736A2 publication Critical patent/WO2007102736A2/en
Publication of WO2007102736A3 publication Critical patent/WO2007102736A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides a method for interfering in activation of an immune cell, comprising providing a substance which specifically interacts in the binding of leukocyte-associated immunoglobulin-like receptor (LAIR) and collagen. The invention in one aspect provides a method for down regulation of activation of an immune cell. In another aspect the invention provides a method for up regulation of activation of an immune cell. The invention further provides pharmaceutical compositions and uses thereof.
PCT/NL2007/050093 2006-03-08 2007-03-08 Interfering in activation of an immune cell by influencing interaction of lair and collagen. Ceased WO2007102736A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07715911A EP2004850A2 (en) 2006-03-08 2007-03-08 Interfering in activation of an immune cell by influencing interaction of lair and collagen.
US12/281,741 US20090304686A1 (en) 2006-03-08 2007-03-08 Interfering in activation of an immune cell by influencing interaction of lair and collagen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06075556.8 2006-03-08
EP06075556 2006-03-08

Publications (2)

Publication Number Publication Date
WO2007102736A2 WO2007102736A2 (en) 2007-09-13
WO2007102736A3 true WO2007102736A3 (en) 2008-03-13

Family

ID=37308805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/050093 Ceased WO2007102736A2 (en) 2006-03-08 2007-03-08 Interfering in activation of an immune cell by influencing interaction of lair and collagen.

Country Status (3)

Country Link
US (1) US20090304686A1 (en)
EP (1) EP2004850A2 (en)
WO (1) WO2007102736A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058948A1 (en) * 2006-10-16 2012-03-08 Stultz Collin M Collagen peptides as immune modulators
EP2036570A1 (en) * 2007-09-13 2009-03-18 UMC Utrecht Holding B.V. Means and methods for influencing platelet-collagen interaction
US20110268741A1 (en) * 2009-01-05 2011-11-03 The Johns Hopkins University Immunotherapy for Contact Dermatitis Using Co-Signal Regulation
BRPI1007483B1 (en) * 2009-01-28 2021-11-30 Bio Preventive Medicine Corporation IN VITRO DIAGNOSIS METHOD OF NEPHROPATHY, IN VITRO METHOD FOR MONITORING THE PROGRESS OF NEPHROPATHY, IN VITRO METHOD FOR MONITORING THE EFFECTIVENESS OF A NEPHROPATHY TREATMENT, IN VITRO METHOD OF EVALUATION OF RENAL TOXICITY OF AN AGENT AND KIT FOR DIAGNOSIS OF NEPHROPATHY
CN109310731B (en) * 2016-04-08 2022-03-29 韩国视角生物株式会社 Extracellular matrix-derived peptide of chondrocyte
KR20190044070A (en) * 2016-08-03 2019-04-29 넥스트큐어 인코포레이티드 Composition and method for modulating LAIR signal transduction
AU2018204986B2 (en) 2017-01-02 2024-08-01 The Board Of Regents Of The University Of Texas System Anti-LAIR1 antibodies and their uses
US11480568B2 (en) 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP4168451A2 (en) * 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
CN118955691B (en) * 2024-10-21 2025-01-28 杭州凯曼健康科技有限公司 Recombinant humanized type XVII collagen and its preparation method and application

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098450A1 (en) * 2001-06-05 2002-12-12 Universitair Medisch Centrum Utrecht Altering an immune response by influencing the interaction of lair with its ligand
WO2003010197A2 (en) * 2001-07-25 2003-02-06 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
WO2003077937A1 (en) * 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20030181392A1 (en) * 2002-03-20 2003-09-25 Schnellmann Ricky Gene Uses of collagen IV
EP1494031A2 (en) * 2003-06-30 2005-01-05 Bayer Healthcare LLC Novel human genes and gene expression products
US6894029B1 (en) * 2000-11-13 2005-05-17 Auburn University Use of jellyfish collagen (type II) in the treatment of rheumatoid arthritis
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US6894029B1 (en) * 2000-11-13 2005-05-17 Auburn University Use of jellyfish collagen (type II) in the treatment of rheumatoid arthritis
WO2002098450A1 (en) * 2001-06-05 2002-12-12 Universitair Medisch Centrum Utrecht Altering an immune response by influencing the interaction of lair with its ligand
WO2003010197A2 (en) * 2001-07-25 2003-02-06 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
WO2003077937A1 (en) * 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20030181392A1 (en) * 2002-03-20 2003-09-25 Schnellmann Ricky Gene Uses of collagen IV
EP1494031A2 (en) * 2003-06-30 2005-01-05 Bayer Healthcare LLC Novel human genes and gene expression products

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KNIGHT C GRAHAM ET AL: "Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen", CARDIOVASCULAR RESEARCH, XX, XX, vol. 41, no. 2, February 1999 (1999-02-01), pages 450 - 457, XP002425787, ISSN: 0008-6363 *
LEBBINK ROBERT JAN ET AL: "The mouse homologue of the leukocyte-associated Ig-like receptor-1 is an inhibitory receptor that recruits Src homology region 2-containing protein tyrosine phosphatase (SHP)-2, but not SHP-1.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAY 2004, vol. 172, no. 9, 1 May 2004 (2004-05-01), pages 5535 - 5543, XP002407123, ISSN: 0022-1767 *
MEYAARD L ET AL: "Leukocyte-Associated Ig-like Receptor-1 functions as an inhibitory receptor on cytotoxic T cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, 1999, pages 5800 - 5804, XP002190968, ISSN: 0022-1767 *
MEYAARD L ET AL: "The Epithelial Cellular Adhesion Molecule (Ep-CAM) is a ligand for the Leukocyte-associated Immunoglobulin-like Receptor (LAIR)", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 194, no. 1, 2 July 2001 (2001-07-02), pages 107 - 112, XP002190969, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
WO2007102736A2 (en) 2007-09-13
EP2004850A2 (en) 2008-12-24
US20090304686A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2007102736A3 (en) Interfering in activation of an immune cell by influencing interaction of lair and collagen.
WO2009034119A8 (en) Improved derivatives of amylin
MY161909A (en) Anti-her3 antibodies and uses thereof
MY171841A (en) Antibody formulation
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2007006049A3 (en) Apparatuses, systems, and methods for isolating and separating biological materials
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2008133938A3 (en) Targeted integration into the ppp1r12c locus
WO2008008917A3 (en) Hydroxyapatite particles
WO2008051942A3 (en) Farnesoid x receptor agonists
IL181618A0 (en) Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof
WO2009036448A3 (en) Natriuretic peptide receptor-c agonists
WO2006083275A3 (en) Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
IL205073A (en) Anti-bst2 antibodies, method for producing them, pharmaceutical compositions comprising them and therir uses
AU2007350983A8 (en) Hydrogen splitting composition
PL1902034T3 (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
MX293459B (en) Emulsifier composition for shortening
WO2010008159A3 (en) Mass- and property-tuned variable mass labeling reagents and analytical methods for simultaneous peptide sequencing and multiplexed protein quantification using thereof
GB201014466D0 (en) Equivalent material constant calculation system, an equivalent material constant calculation program, equivalent material constant calculation method,
WO2009152167A3 (en) Delivery of therapeutics
WO2008113916A9 (en) Pharmaceutical composition containing antibodies directed against the herv-w envelope
WO2007001962A3 (en) Systems and methods for generating biological material

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007715911

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12281741

Country of ref document: US